AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Palatin Technologies, the manufacturer of NeutroSpec, is voluntarily suspending the sales and marketing of the radiodiagnostic agent in the United States, according to a public health advisory issued by the Food and Drug Administration. The action is being taken "pending review of reported and serious life-threatening adverse events associated with use of the product," according to the FDA.
NeutroSpec [Technetium (99m Tc) fanolesomab] an imaging agent comprising a murine IgM monoclonal antibody labeled with technetium, is approved for scintigraphic imaging of patients with equivocal signs and symptoms of appendicitis who are 5 years of age or older.
Two deaths attributed to cardiopulmonary failure within 30 minutes of injection have been reported, as have additional cases of serious events including cardiac arrest, hypoxia, dyspnea, and hypotension. Most of these adverse events occurred within minutes of injection and required patient resuscitation with fluids, vasopressors, and oxygen.
Although the majority of the reports involved patients receiving ...